Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 in Relapsed or Refractory Multiple Myeloma
NCT01058434Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of dovitinib in multiple myeloma (MM), sponsored by Novartis. Started May 2010; status: completed.
02
Drugs
dovitinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01058434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058434.